Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04776837 · ClinicalTrials.gov registry record
Predicting Disease Progression and/or Recurrence in Cancer
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 159
- Enrollment target
NCT04776837: Completed study, sponsored by Massachusetts General Hospital.
NCT04776837 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 159 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04776837 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 159 participants
- Enrollment target
Study Summary
This is a prospective study addressing the challenge of predicting disease progression and/or recurrence in patients diagnosed with metastatic colorectal, pancreatobiliary, or esophagogastric cancer that are receiving anti-cancer therapy.
Interventions
- BEHAVIORAL Observational Cohort
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2019-05-15 |
| Est. Completion | 2022-10-19 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04776837
The ClinicalTrials.gov registry entry for NCT04776837 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Observational Cohort is the first listed.
NCT04776837 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04776837 about?
NCT04776837 is a clinical study titled "Predicting Disease Progression and/or Recurrence in Cancer". This is a prospective study addressing the challenge of predicting disease progression and/or recurrence in patients diagnosed with metastatic colorectal, pancreatobiliary, or esophagogastric cancer that are receiving anti-cancer therapy.
What is the current status of trial NCT04776837?
This trial is currently completed. The enrollment target is 159 participants. The study started on 2019-05-15. Estimated completion is 2022-10-19.
What interventions are being tested in trial NCT04776837?
The interventions under investigation include: Observational Cohort (BEHAVIORAL).
Who is sponsoring clinical trial NCT04776837?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.